CD4 and CD8 T Lymphocyte Interplay in Controlling Tumor Growth

Overview

Journal Cell Mol Life Sci

Publisher Springer

Specialty Biology

Date 2017 Oct 17

PMID 29032503

Citations 271

Authors

Dmitrij Ostroumov

Nora Fekete-Drimusz

Michael Saborowski

Florian Kuhnel

Norman Woller

Affiliations

Soon will be listed here.

Abstract

The outstanding clinical success of immune checkpoint blockade has revived the interest in underlying mechanisms of the immune system that are capable of eliminating tumors even in advanced stages. In this scenario, CD4 and CD8 T cell responses are part of the cancer immune cycle and both populations significantly influence the clinical outcome. In general, the immune system has evolved several mechanisms to protect the host against cancer. Each of them has to be undermined or evaded during cancer development to enable tumor outgrowth. In this review, we give an overview of T lymphocyte-driven control of tumor growth and discuss the involved tumor-suppressive mechanisms of the immune system, such as senescence surveillance, cancer immunosurveillance, and cancer immunoediting with respect to recent clinical developments of immunotherapies. The main focus is on the currently existing knowledge about the CD4 and CD8 T lymphocyte interplay that mediates the control of tumor growth.

Citing Articles

Prognostic significance of the hemoglobin, albumin, lymphocyte, platelet (HALP) score after hepatectomy for colorectal liver metastases.

Okazaki K, Furukawa K, Haruki K, Onda S, Shirai Y, Tsunematsu M Surg Today. 2025; .

PMID: 39828751 DOI: 10.1007/s00595-025-02993-4.

HALP Score in Predicting Response to Treatment in Patients with Early-Stage Gastric Cancer: A Multi-Centred Retrospective Cohort Study.

Koseci T, Seyyar M, Aydinalp Camadan Y, Celik H, Mete B, Demirhindi H Medicina (Kaunas). 2025; 60(12.

PMID: 39768966 PMC: 11678702. DOI: 10.3390/medicina60122087.

LADS: a powerful vaccine platform for cancer immunotherapy and prevention.

Sun J, Wang J, Jiang X, Xia J, Han Y, Chen M BMC Biol. 2024; 22(1):291.

PMID: 39696249 PMC: 11656817. DOI: 10.1186/s12915-024-02086-7.

Can HALP (Hemoglobin, albumin, lymphocyte, and platelet) score distinguish malignant and benign causes of extrahepatic cholestasis in patients with extrahepatic bile duct obstruction?.

Dusunceli I, Sargin Z, Celik U, Sargin F North Clin Istanb. 2024; 11(6):555-559.

PMID: 39650317 PMC: 11622744. DOI: 10.14744/nci.2024.23169.

Identifying the signature of NAD+ metabolism-related genes for immunotherapy of gastric cancer.

Wen H, Mi Y, Li F, Xue X, Sun X, Zheng P Heliyon. 2024; 10(20):e38823.

PMID: 39640811 PMC: 11620085. DOI: 10.1016/j.heliyon.2024.e38823.

References

Koebel C, Vermi W, Swann J, Zerafa N, Rodig S, Old L . Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007; 450(7171):903-7. DOI: 10.1038/nature06309. View

Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

Steiner G, Newman M, Paikl D, Stix U, Memaran-Dagda N, Lee C . Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003; 56(3):171-82. DOI: 10.1002/pros.10238. View

Cao X, Cai S, Fehniger T, Song J, Collins L, Piwnica-Worms D . Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity. 2007; 27(4):635-46. DOI: 10.1016/j.immuni.2007.08.014. View

Knutson K, Disis M . Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005; 54(8):721-8. PMC: 11032889. DOI: 10.1007/s00262-004-0653-2. View

Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E . Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 1999; 59(15):3698-704. View

Selby M, Engelhardt J, Quigley M, Henning K, Chen T, Srinivasan M . Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res. 2014; 1(1):32-42. DOI: 10.1158/2326-6066.CIR-13-0013. View

Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M . NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008; 36(Web Server issue):W509-12. PMC: 2447772. DOI: 10.1093/nar/gkn202. View

Babiker H, Riaz I, Husnain M, Borad M . Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother. 2017; 6:11-18. PMC: 5308590. DOI: 10.2147/OV.S100072. View

10.

Knocke S, Fleischmann-Mundt B, Saborowski M, Manns M, Kuhnel F, Wirth T . Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer. Cell Rep. 2016; 17(9):2234-2246. DOI: 10.1016/j.celrep.2016.10.086. View

11.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

12.

Zamarin D, Holmgaard R, Subudhi S, Park J, Mansour M, Palese P . Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med. 2014; 6(226):226ra32. PMC: 4106918. DOI: 10.1126/scitranslmed.3008095. View

13.

Apetoh L, Smyth M, Drake C, Abastado J, Apte R, Ayyoub M . Consensus nomenclature for CD8 T cell phenotypes in cancer. Oncoimmunology. 2015; 4(4):e998538. PMC: 4485711. DOI: 10.1080/2162402X.2014.998538. View

14.

Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H . CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998; 58(16):3491-4. View

15.

Oderup C, Cederbom L, Makowska A, Cilio C, Ivars F . Cytotoxic T lymphocyte antigen-4-dependent down-modulation of costimulatory molecules on dendritic cells in CD4+ CD25+ regulatory T-cell-mediated suppression. Immunology. 2006; 118(2):240-9. PMC: 1782280. DOI: 10.1111/j.1365-2567.2006.02362.x. View

16.

Ghiringhelli F, Puig P, Roux S, Parcellier A, Schmitt E, Solary E . Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. 2005; 202(7):919-29. PMC: 2213166. DOI: 10.1084/jem.20050463. View

17.

Khong H, Restifo N . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002; 3(11):999-1005. PMC: 1508168. DOI: 10.1038/ni1102-999. View

18.

Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J . Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature. 2015; 520(7549):692-6. PMC: 4838069. DOI: 10.1038/nature14426. View

19.

Marzo A, Lake R, Robinson B, Scott B . T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 1999; 59(5):1071-9. View

20.

Quezada S, Simpson T, Peggs K, Merghoub T, Vider J, Fan X . Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 2010; 207(3):637-50. PMC: 2839156. DOI: 10.1084/jem.20091918. View